ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations. The Company's lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (MET) and its biological pathway. The Company's product candidates include ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to inhibit the fibroblast growth factor receptor (FGFR) family, and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQO1-mediated programmed cancer cell necrosis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ARQL
- CUSIP: 04269E10
- Previous Close: $1.26
- 50 Day Moving Average: $1.44
- 200 Day Moving Average: $1.44
- 52-Week Range: $1.13 - $2.17
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.53
- P/E Growth: -0.76
- Market Cap: $88.90M
- Outstanding Shares: 71,118,000
- Beta: 1.51
- Net Margins: -296.69%
- Return on Equity: -55.62%
- Return on Assets: -43.73%
Companies Related to ArQule:
- Current Ratio: 4.51%
- Quick Ratio: 4.51%
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
Where is ArQule's stock going? Where will ArQule's stock price be in 2017?
1 brokers have issued 12 month target prices for ArQule's shares. Their predictions range from $2.50 to $2.50. On average, they anticipate ArQule's stock price to reach $2.50 in the next twelve months.
When will ArQule announce their earnings?
ArQule is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns ArQule stock?
ArQule's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.84%), FMR LLC (1.03%) and Dimensional Fund Advisors LP (0.15%). Company insiders that own ArQule stock include Michael D Loberg, Paolo Pucci and Patrick J Zenner.
Who sold ArQule stock? Who is selling ArQule stock?
ArQule's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP.
Who bought ArQule stock? Who is buying ArQule stock?
ArQule's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought ArQule stock in the last two years include Michael D Loberg, Paolo Pucci and Patrick J Zenner.
How do I buy ArQule stock?
Shares of ArQule can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of ArQule stock cost?
One share of ArQule stock can currently be purchased for approximately $1.27.